Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS).

Chen CH, Elsalmawy AH, Ish-Shalom S, Lim SJ, Al-Ali NS, Cunha-Borges JL, Yang H, Casas N, Altan L, Moll T, Gurbuz S, Brnabic AJM, Burge RT, Marin F.

Curr Med Res Opin. 2019 Jan 3:1-9. doi: 10.1080/03007995.2018.1552576. [Epub ahead of print]

PMID:
30474449
2.

Gendered bio-responsibilities and travelling egg providers from South Africa.

Pande A, Moll T.

Reprod Biomed Soc Online. 2018 Sep 19;6:23-33. doi: 10.1016/j.rbms.2018.08.002. eCollection 2018 Aug.

3.

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A.

Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.

PMID:
30388455
4.

Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0247-8.

PMID:
30333558
5.

Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis.

Moss RB, Moll T, Daniels K, Carlo DJ.

Allergy Asthma Proc. 2018 Sep 1;39(5):389-393. doi: 10.2500/aap.2018.39.4154.

PMID:
30153890
6.

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.

Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E.

Nat Med. 2018 Oct;24(10):1545-1549. doi: 10.1038/s41591-018-0157-9. Epub 2018 Aug 20. Erratum in: Nat Med. 2018 Dec;24(12):1942.

PMID:
30127394
7.

Simultaneous CRISPR/Cas9-mediated editing of cassava eIF4E isoforms nCBP-1 and nCBP-2 reduces cassava brown streak disease symptom severity and incidence.

Gomez MA, Lin ZD, Moll T, Chauhan RD, Hayden L, Renninger K, Beyene G, Taylor NJ, Carrington JC, Staskawicz BJ, Bart RS.

Plant Biotechnol J. 2019 Feb;17(2):421-434. doi: 10.1111/pbi.12987. Epub 2018 Oct 5.

8.

Molecular profiling of reticular gigantocellularis neurons indicates that eNOS modulates environmentally dependent levels of arousal.

Tabansky I, Liang Y, Frankfurt M, Daniels MA, Harrigan M, Stern S, Milner TA, Leshan R, Rama R, Moll T, Friedman JM, Stern JNH, Pfaff DW.

Proc Natl Acad Sci U S A. 2018 Jul 17;115(29):E6900-E6909. doi: 10.1073/pnas.1806123115. Epub 2018 Jul 2.

9.

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).

Napoli N, Langdahl BL, Ljunggren Ö, Lespessailles E, Kapetanos G, Kocjan T, Nikolic T, Eiken P, Petto H, Moll T, Lindh E, Marin F.

Calcif Tissue Int. 2018 Jun 16. doi: 10.1007/s00223-018-0437-x. [Epub ahead of print]

10.

Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector.

Moss RB, Daniels K, Moll T, Carlo DJ.

Ann Allergy Asthma Immunol. 2018 May;120(5):540-541. doi: 10.1016/j.anai.2018.02.027. Epub 2018 Feb 27. No abstract available.

11.

Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).

Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Kapetanos G, Kocjan T, Lespessailles E, Napoli N, Nikolic T, Petto H, Moll T, Lindh E.

Calcif Tissue Int. 2016 Sep;99(3):259-71. doi: 10.1007/s00223-016-0143-5. Epub 2016 Apr 30.

12.

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G.

Invest New Drugs. 2016 Apr;34(2):225-30. doi: 10.1007/s10637-016-0334-y. Epub 2016 Feb 29.

PMID:
26924129
13.

Loss of CMD2-mediated resistance to cassava mosaic disease in plants regenerated through somatic embryogenesis.

Beyene G, Chauhan RD, Wagaba H, Moll T, Alicai T, Miano D, Carrington JC, Taylor NJ.

Mol Plant Pathol. 2016 Sep;17(7):1095-110. doi: 10.1111/mpp.12353. Epub 2016 Apr 5.

14.

"Put your Hands up in the Air"? The interpersonal effects of pride and shame expressions on opponents and teammates.

Furley P, Moll T, Memmert D.

Front Psychol. 2015 Sep 8;6:1361. doi: 10.3389/fpsyg.2015.01361. eCollection 2015.

15.

Self-report measurement of pain & symptoms in palliative care patients: a comparison of verbal, visual and hand scoring methods in Sub-Saharan Africa.

Blum D, Selman LE, Agupio G, Mashao T, Mmoledi K, Moll T, Dinat N, Gwyther L, Sebuyira LM, Ikin B, Downing J, Kaasa S, Higginson IJ, Harding R.

Health Qual Life Outcomes. 2014 Aug 2;12:118. doi: 10.1186/s12955-014-0118-z.

16.

The ARSQ: the athletes' received support questionnaire.

Freeman P, Coffee P, Moll T, Rees T, Sammy N.

J Sport Exerc Psychol. 2014 Apr;36(2):189-202. doi: 10.1123/jsep.2013-0080.

PMID:
24686955
17.

Star-shaped poly(styrene)-block-poly(4-vinyl-N-methylpyridiniumiodide) for semipermanent antimicrobial coatings.

Siedenbiedel F, Fuchs A, Moll T, Weide M, Breves R, Tiller JC.

Macromol Biosci. 2013 Oct;13(10):1447-55. doi: 10.1002/mabi.201300219. Epub 2013 Jul 30.

PMID:
23897664
18.

'Peace' and 'life worthwhile' as measures of spiritual well-being in African palliative care: a mixed-methods study.

Selman L, Speck P, Gysels M, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Ikin B, Higginson IJ, Harding R.

Health Qual Life Outcomes. 2013 Jun 10;11:94. doi: 10.1186/1477-7525-11-94.

19.

How to analyze palliative care outcome data for patients in Sub-Saharan Africa: an international, multicenter, factor analytic examination of the APCA African POS.

Harding R, Selman L, Simms VM, Penfold S, Agupio G, Dinat N, Downing J, Gwyther L, Ikin B, Mashao T, Mmoledi K, Sebuyira LM, Moll T, Mwangi-Powell F, Namisango E, Powell RA, Walkey FH, Higginson IJ, Siegert RJ.

J Pain Symptom Manage. 2013 Apr;45(4):746-52. doi: 10.1016/j.jpainsymman.2012.04.007. Epub 2012 Sep 24.

20.

Prevalence, burden, and correlates of physical and psychological symptoms among HIV palliative care patients in sub-Saharan Africa: an international multicenter study.

Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Ikin B, Higginson IJ.

J Pain Symptom Manage. 2012 Jul;44(1):1-9. doi: 10.1016/j.jpainsymman.2011.08.008. Epub 2012 Jun 1.

PMID:
22658471
21.

The "Spirit 8" successfully captured spiritual well-being in African palliative care: factor and Rasch analysis.

Selman L, Siegert RJ, Higginson IJ, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Ikin B, Harding R.

J Clin Epidemiol. 2012 Apr;65(4):434-43. doi: 10.1016/j.jclinepi.2011.09.014.

PMID:
22360991
22.

Quality of life among patients receiving palliative care in South Africa and Uganda: a multi-centred study.

Selman LE, Higginson IJ, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Ikin B, Harding R.

Health Qual Life Outcomes. 2011 Apr 8;9:21. doi: 10.1186/1477-7525-9-21.

23.

The MVQOLI successfully captured quality of life in African palliative care: a factor analysis.

Selman L, Siegert RJ, Higginson IJ, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Ikin B, Harding R.

J Clin Epidemiol. 2011 Aug;64(8):913-24. doi: 10.1016/j.jclinepi.2010.12.013. Epub 2011 Apr 6.

PMID:
21474280
24.

Local anaesthetic toxicity: are we prepared for the consequences in the Emergency Department?

Cooper BR, Moll T, Griffiths JR.

Emerg Med J. 2010 Aug;27(8):599-602. doi: 10.1136/emj.2009.079038.

PMID:
20688937
25.

Emotional contagion in soccer penalty shootouts: celebration of individual success is associated with ultimate team success.

Moll T, Jordet G, Pepping GJ.

J Sports Sci. 2010 Jul;28(9):983-92. doi: 10.1080/02640414.2010.484068.

PMID:
20544488
26.

Validation of a core outcome measure for palliative care in Africa: the APCA African Palliative Outcome Scale.

Harding R, Selman L, Agupio G, Dinat N, Downing J, Gwyther L, Mashao T, Mmoledi K, Moll T, Sebuyira LM, Panjatovic B, Higginson IJ.

Health Qual Life Outcomes. 2010 Jan 25;8:10. doi: 10.1186/1477-7525-8-10.

27.

In vivo over-expression of interleukin-10 increases resistance to focal brain ischemia in mice.

de Bilbao F, Arsenijevic D, Moll T, Garcia-Gabay I, Vallet P, Langhans W, Giannakopoulos P.

J Neurochem. 2009 Jul;110(1):12-22. doi: 10.1111/j.1471-4159.2009.06098.x. Epub 2009 Apr 16.

28.

Protection of murine systemic lupus by the Ea transgene without expression of I-E heterodimers.

Martínez-Soria E, Santiago-Raber ML, Ho L, Moll T, Izui S.

J Immunol. 2008 Sep 1;181(5):3651-7.

29.

Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa.

Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G; Tugela Ferry Care and Research (TF CARES) Collaboration.

J Infect Dis. 2007 Dec 1;196 Suppl 3:S482-90. doi: 10.1086/521121. Review.

PMID:
18181698
30.

Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function.

Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, Kuchroo VK.

J Exp Med. 2007 Jul 9;204(7):1691-702. Epub 2007 Jul 2.

31.

TB on the back burner, losing curable status.

Moll T.

Int J Tuberc Lung Dis. 2007 Apr;11(4):355. No abstract available.

PMID:
17394679
32.

CD8(+) T cells resistant to costimulatory blockade are controlled by an antagonist interleukin-15/Fc protein.

Ferrari-Lacraz S, Zheng XX, Fueyo AS, Maslinski W, Moll T, Strom TB.

Transplantation. 2006 Dec 15;82(11):1510-7.

34.

Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus.

Kikuchi S, Santiago-Raber ML, Amano H, Amano E, Fossati-Jimack L, Moll T, Kotzin BL, Izui S.

J Immunol. 2006 Mar 1;176(5):3240-7.

35.

An antagonist mutant IL-15/Fc promotes transplant tolerance.

Zheng XX, Gao W, Donskoy E, Neuberg M, Ruediger M, Strom TB, Moll T.

Transplantation. 2006 Jan 15;81(1):109-16.

36.

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma.

Encinas JA, Janssen EM, Weiner DB, Calarota SA, Nieto D, Moll T, Carlo DJ, Moss RB.

J Allergy Clin Immunol. 2005 Dec;116(6):1343-9. Epub 2005 Oct 3.

PMID:
16337469
37.

Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding.

Nitschke L, Lajaunias F, Moll T, Ho L, Martinez-Soria E, Kikuchi S, Santiago-Raber ML, Dix C, Parkhouse RM, Izui S.

Int Immunol. 2006 Jan;18(1):59-68. Epub 2005 Nov 15.

PMID:
16291654
38.

Selective expansion of a monocyte subset expressing the CD11c dendritic cell marker in the Yaa model of systemic lupus erythematosus.

Amano H, Amano E, Santiago-Raber ML, Moll T, Martinez-Soria E, Fossati-Jimack L, Iwamoto M, Rozzo SJ, Kotzin BL, Izui S.

Arthritis Rheum. 2005 Sep;52(9):2790-8.

39.

Identification of 2 major loci linked to autoimmune hemolytic anemia in NZB mice.

Kikuchi S, Amano H, Amano E, Fossati-Jimack L, Santiago-Raber ML, Moll T, Ida A, Kotzin BL, Izui S.

Blood. 2005 Aug 15;106(4):1323-9. Epub 2005 Apr 28.

40.

The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis.

Prandini MH, Dreher I, Bouillot S, Benkerri S, Moll T, Huber P.

Oncogene. 2005 Apr 21;24(18):2992-3001.

41.

Differential role of three major New Zealand Black-derived loci linked with Yaa-induced murine lupus nephritis.

Kikuchi S, Fossati-Jimack L, Moll T, Amano H, Amano E, Ida A, Ibnou-Zekri N, Laporte C, Santiago-Raber ML, Rozzo SJ, Kotzin BL, Izui S.

J Immunol. 2005 Jan 15;174(2):1111-7.

42.

Differential activation of anti-erythrocyte and anti-DNA autoreactive B lymphocytes by the Yaa mutation.

Moll T, Martinez-Soria E, Santiago-Raber ML, Amano H, Pihlgren-Bosch M, Marinkovic D, Izui S.

J Immunol. 2005 Jan 15;174(2):702-9.

43.

Th1/Th2 cells in inflammatory disease states: therapeutic implications.

Moss RB, Moll T, El-Kalay M, Kohne C, Soo Hoo W, Encinas J, Carlo DJ.

Expert Opin Biol Ther. 2004 Dec;4(12):1887-96. Review.

PMID:
15571451
44.

Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis.

Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, Zheng XX, Hancock WW, Maslinski W, Li XC, Strom TB, Moll T.

J Immunol. 2004 Nov 1;173(9):5818-26.

45.

A critical role for Fc gamma RIIB in the induction of rheumatoid factors.

Moll T, Nitschke L, Carroll M, Ravetch JV, Izui S.

J Immunol. 2004 Oct 1;173(7):4724-8.

46.

Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients.

Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, Sybrecht GW, Lalvani A, Köhler H.

Kidney Int. 2004 May;65(5):1826-34.

47.

Enforced Bcl-2 expression in B lymphocytes induces rheumatoid factor and anti-DNA production, but the Yaa mutation promotes only anti-DNA production.

Kuroki A, Moll T, López-Hoyos M, Fossati-Jimack L, Ibnou-Zekri N, Kikuchi S, Merino J, Merino R, Izui S.

Eur J Immunol. 2004 Apr;34(4):1077-84.

48.

Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus.

Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, Law CL, Izui S.

Arthritis Rheum. 2003 Jun;48(6):1612-21.

49.

The Yaa mutation promoting murine lupus causes defective development of marginal zone B cells.

Amano H, Amano E, Moll T, Marinkovic D, Ibnou-Zekri N, Martinez-Soría E, Semac I, Wirth T, Nitschke L, Izui S.

J Immunol. 2003 Mar 1;170(5):2293-301.

50.

Differentially regulated expression and function of CD22 in activated B-1 and B-2 lymphocytes.

Lajaunias F, Nitschke L, Moll T, Martinez-Soria E, Semac I, Chicheportiche Y, Parkhouse RM, Izui S.

J Immunol. 2002 Jun 15;168(12):6078-83.

Supplemental Content

Support Center